U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Core Viewpoint - Liquidia Corporation has received FDA approval for YUTREPIA™ (treprostinil) inhalation powder, a new treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) aimed at improving exercise ability [1][4] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, utilizing its proprietary PRINT™ technology to create drug formulations [10] Product Details - YUTREPIA is the first and only prostacyclin dry-powder formulation designed for deep-lung delivery using a low-effort inhalation device, enhancing patient experience [1][7] - The approval of YUTREPIA is based on the Phase 3 INSPIRE trial, which demonstrated its safety and tolerability for patients naïve to treprostinil and those transitioning from nebulized forms [2][7] Market Impact - The introduction of YUTREPIA provides a new treatment option for over 105,000 patients in the U.S. suffering from PAH and PH-ILD, addressing a significant unmet medical need [2][5] - The product is expected to improve the quality of life for patients, as highlighted by industry leaders and patient advocacy groups [2][6] Legal Considerations - United Therapeutics Corporation has filed a complaint against Liquidia alleging patent infringement related to YUTREPIA, which may impact its commercialization [2][10] Upcoming Events - Liquidia plans to host a live webcast on May 27, 2025, to provide updates on the commercial launch preparations for YUTREPIA [3][4]